Volume 13, Issue 4 (Int J Mol Cell Med 2024)                   Int J Mol Cell Med 2024, 13(4): 361-373 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sadeghipour A, Mohagheghian H, Movahedinia S, Kosari F, Monabati A. O-6-Methylguanine-DNA Methyltransferase, C-MYC, and EBER Status in Diffuse Large B-Cell Lymphoma of Central Nervous System. Int J Mol Cell Med 2024; 13 (4) :361-373
URL: http://ijmcmed.org/article-1-2430-en.html
O-6-Methylguanine-DNA Methyltransferase, C-MYC, and EBER Status in Diffuse Large B-Cell Lymphoma of Central Nervous System
Alireza Sadeghipour1 , Hadi Mohagheghian2 , Sajjadeh Movahedinia3 , Farid Kosari4 , Ahmad Monabati5
1- Department of Pathology, Oncopathology Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
2- Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
3- Department of Molecular Pathology and Cytogenetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. , sajjadeh.movahedinia@gmail.com
4- Department of Hematopathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
5- Department of Hematopathology and Molecular Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract:   (581 Views)
Diffuse Large B-cell Lymphoma (DLBCL), the most common type of primary central nervous system lymphoma (PCNSL), is a rare aggressive subtype of DLBCL with a poorly understood biology. This study aimed to investigate the prevalence of O-6-Methylguanine-DNA Methyltransferase (MGMT), C-MYC and Epstein-Barr virus Encoded RNA (EBER) positivity in CNS-DLBCLs. Using tissue microarray method, formalin-fixed paraffin-embedded blocks of 76 cases of confirmed PCNS-DLBCL and 2 cases of immunodeficiency-related CNS DLBCL were examined for EBER and C-MYC by chromogenic in situ hybridization (CISH), and for MGMT, CD10, BCL2, BCL6, MUM1 and Ki67 by Immunohistochemistry (IHC). The results were analyzed in association with histopathologic and demographic characteristics. The majority of the tumors were of non-germinal center B-cell (non-GCB) type. Loss of MGMT expression on IHC, as a surrogate marker of MGMT methylation, was detected in about 68.9% of PCNSLs. Preserved MGMT expression was found to occur more frequently in males and in MUM1-negative and GCB-type tumors. EBER positivity was exclusively seen in immunodeficient cases. Low C-MYC amplification was detected in 18% of cases and showed association with BCL2 and Ki67 expression. We concluded that loss of MGMT expression is a common phenomenon in PCNSLs. Epstein-Barr virus (EBV) may not be commonly detected in PCNS-DLBCL as frequently as in systemic DLBCL, but its expression is inevitable in CNS-DLBCLs of immunocompromised ones. Maintained MGMT expression is associated with less aggressive histopathologic features. Further studies are warranted to confirm the prognostic significance of loss of MGMT expression in PCNSLs and its potential use for predicting therapeutic response to alkylating agents in PCNSLs.
Keywords: Primary central nervous system lymphoma, diffuse large B-cell lymphoma, MYC, EBER, MGMT, O-6-methylguanine-DNA methyltransferase
Full-Text [PDF 621 kb]   (244 Downloads)    
Type of Study: Original Article | Subject: Biomarkers (diagnosis & treatment)
Received: 2024/09/3 | Accepted: 2024/10/30 | Published: 2024/11/30
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | International Journal of Molecular and Cellular Medicine IJMCM

Designed & Developed by : Yektaweb